Skip to content

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01353846
Enrollment
70
Registered
2011-05-16
Start date
2011-05-31
Completion date
2012-11-30
Last updated
2012-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

oocyte donation program, natural cycle, hormone replacement therapy

Brief summary

The purpose of this study is to compare the natural cycle (without any medication) with the well-established artificial cycle in an egg donation program.

Detailed description

Oocyte donation is an assisted reproduction technique well established. In patients with ovarian function, it is necessary to synchronize the cycle of the egg donor with the recipient, usually through endometrial preparation of the recipient by artificial cycle, by administering a GnRH agonist on day 21 of cycle and then administered increasing doses of estrogen therapy to achieve adequate endometrial thickness. The necessity of synchronization between donors and recipient, has made possible not routinely the natural cycle for oocyte donation. The investigators have recently introduced oocyte vitrification and it allows us to plan the egg donation in a different way. Now the investigators can previously cryopreserved donor oocytes and at the time that the investigators have a compatible receiver, then, plan the donation In this study it will be possible compare the results of oocyte donation cycles in terms of pregnancy rate, implantation and liveborn, depending on whether the recipient has made an artificial cycle of preparation endometrial or a natural cycle.

Interventions

OTHERobservation natural cycle

The patients natural reproductive cycle will be observed and compared to the second arm.

DRUGAgonist GnRH; estradiol Valerate; progesterone

Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration

Sponsors

Instituto Valenciano de Infertilidad, IVI VALENCIA
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* infertile females with preserved gonadal function * ages 18 - 44 years old included * first oocyte donation cycle

Exclusion criteria

* BMI: \> 28 * recurrent miscarriages (3 or more) * recurrent of implantation failure * severe male factor * important miomas * \> 44 years old * Problems with the drugs used in the study

Design outcomes

Primary

MeasureTime frameDescription
Preparation and treatment for Assisted Human Reproduction procedures and in the case opf pregnancy, follow up.12 monthsOutcome of the study is measured by the pregnancy rates after IVF treatments of both arms.

Countries

Spain

Contacts

Primary ContactDra. Pilar Alamá
pilar.alama@ivi.es+34963050900
Backup ContactLeslie Atkinson
leslie.atkinson@ivi.es+34963050900

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026